

AMENDMENTS TO THE CLAIMS

Claim 1. (Currently Amended) A method for the treatment of one or more of (a) non-inflammatory bowel disease, (b) diverticulosis, (c) diverticulitis, (d) diarrhoea-predominant irritable bowel syndrome, (e) irritable bowel syndrome, (f) one or more of bloating, diarrhoea, cramping, pain, low abdominal pain, distension, wind, flatulence, gas production, fluid secretion, mucus production, constipation, urgency or incontinence, when associated with a non-inflammatory bowel disease, diarrhoea-predominant irritable bowel syndrome or other non-specific non-inflammatory bowel disorder, (g) non ulcer dyspepsia, (h) spastic colon, (i) unstable colonic neurosis, (j) spastic colitis, (k) mucous colitis, (l) alternating constipation/diarrhoea, (m) alternating diarrhoea and constipation type IBS or (n) constipation IBS, comprising administering to a patient in need of such treatment an effective amount of balsalazide or a salt thereof and rifaximin or a composition comprising balsalazide or a salt thereof and rifaximin together with a suitable carrier.

Claim 2. (original) A method according to claim 1 wherein the method alleviates symptoms of alternating diarrhoea and constipation type Irritable Bowel Syndrome or constipation predominant Irritable Bowel Syndrome.

Claim 3. (cancelled)

Claim 4. (original) A method according to claim 1 wherein the patient is a mammal.

Claim 5. (original) A method according to claim 4 wherein the patient is a human.

Claim 6. (Currently Amended) A method according to claim 1 wherein balsalazide and rifaximin are [[is]] administered together with one or more of a 4-aminosalicylic acid or 5-aminosalicylic acid compound.

Claim 7. (Previously Presented) A method according to claim 6 wherein the 5-aminosalicylic acid or 4-aminosalicylic acid compound is mesalazine, olsalazine, sulfasalazine,

ipsalazide, benzalazine, para-amino salicylic acid and pharmaceutically acceptable salts thereof.

Claim 8. (Currently Amended) A method according to claim 1 wherein balsalazide is administered together with ~~o~~lsalazine~~er~~ifaximin for the treatment of diarrhoea predominant, constipation predominant or alternating diarrhoea and constipation type Irritable Bowel Syndrome.

Claim 9. (Currently Amended) A method according to claim 1 wherein balsalazide is administered together with ~~mesalazine~~erifaximin for the treatment of ~~diarrhoea predominant Irritable Bowel Syndrome~~diverticulitis.

Claim 10. (Cancelled)

Claim 11. (Cancelled)

Claims 12-13. (cancelled)